Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference
March 01, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose to Participate in Two Biotech Events in January 2022
December 29, 2021 07:30 ET
|
Aptose Biosciences, Inc.
— H.C. Wainwright BIOCONNECT Virtual Conference — — 11th Annual LifeSci Partners Corporate Access Event — SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc....
Aptose Provides Update on APTO-253 Program
December 20, 2021 07:30 ET
|
Aptose Biosciences, Inc.
-- Clinical development of the MYC repressor APTO-253 will be discontinued -- -- Company will focus on advancing kinome inhibitor pipeline -- SAN DIEGO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE)...
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
December 13, 2021 16:30 ET
|
Aptose Biosciences, Inc.
HM43239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting Aptose Presents Highlights from Luxeptinib and APTO-253 and Provides Corporate Update SAN DIEGO,...
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021
October 26, 2021 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose Expands Senior Leadership Team
October 25, 2021 08:00 ET
|
Aptose Biosciences, Inc.
Janet Clennett, CPA, appointed Vice President, Finance Roger Davies, B.Sc., M. Phil, joins as Vice President, Operations SAN DIEGO and TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences...
Aptose to Present at September Investor Conferences
August 30, 2021 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021
July 20, 2021 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
June 01, 2021 16:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose to Hold Corporate Update Friday, June 11th
May 27, 2021 07:30 ET
|
Aptose Biosciences, Inc.
Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at EHA2021 Virtual...